XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.19.1

Disaggregation of Revenues, Geographic Sales and Product Sales | 3 Months Ended
--- | ---
Mar. 29, 2019
Segment Reporting [Abstract] |
Disaggregation of Revenues, Geographic Sales and Product Sales | Note 14 — Disaggregation of Revenues, Geographic Sales and Product Sales In the following tables, revenues are disaggregated by category, sales by geographic market and sales by product data. The following breaks down revenues into the following categories (in thousands):
|  | Three Months Ended |
|  | March 29, 2019 |  |  | March 30, 2018 |
Non-consignment sales |  | $ | 28,266 |  |  | $ | 22,181 |
Consignment sales |  |  | 4,317 |  |  |  | 4,912 |
Total net sales |  | $ | 32,583 |  |  | $ | 27,093 |
Note 14 — Disaggregation of Revenues, Geographic Sales and Product Sales (Continued) The Company markets and sells its products in over 75 countries and conducts its manufacturing in the United States. Other than China, Japan and Korea, the Company does not conduct business in any country in which its sales exceed 10% of worldwide consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers is set forth below (in thousands):
|  | Three Months Ended |
|  | March 29, 2019 |  |  | March 30, 2018 |
China |  | $ | 11,771 |  |  | $ | 7,910 |
Japan |  |  | 5,519 |  |  |  | 5,083 |
Korea |  |  | 3,291 |  |  |  | 2,195 |
Other(1) |  |  | 12,002 |  |  |  | 11,905 |
Total net sales |  | $ | 32,583 |  |  | $ | 27,093 |
(1) | No other location individually exceeds 10% of the total sales.
In addition, domestic and foreign sales are as follows (in thousands):
|  | Three Months Ended |
|  | March 29, 2019 |  |  | March 30, 2018 |
Domestic |  | $ | 1,952 |  |  | $ | 1,756 |
Foreign |  |  | 30,631 |  |  |  | 25,337 |
Total net sales |  | $ | 32,583 |  |  | $ | 27,093 |
100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery. The composition of the Company’s net sales by product line is as follows (in thousands):
|  | Three Months Ended |
|  | March 29, 2019 |  |  | March 30, 2018 |
ICLs |  | $ | 27,786 |  |  | $ | 21,158 |
Other product sales |  |  |  |  |  |  |  |
IOLs |  |  | 4,017 |  |  |  | 4,058 |
Other surgical products |  |  | 780 |  |  |  | 1,877 |
Total other product sales |  |  | 4,797 |  |  |  | 5,935 |
Total net sales |  | $ | 32,583 |  |  | $ | 27,093 |
One customer, our distributor in China, accounted for 36% and 29% of net sales for the three months ended March 29, 2019 and March 30, 2018, respectively. As of March 29, 2019 and December 28, 2018, respectively, one customer, our distributor in China, accounted for 37% and 36% of consolidated trade receivables.

X
- Definition The entire disclosure for disaggregation of revenues, geographic sales and product sales. + References No definition available. + Details
Name: | staa_DisaggregationOfRevenuesGeographicSalesAndProductSalesDisclosureTextBlock
Namespace Prefix: | staa_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration